Home » Topics » BioWorld Science, Conferences

BioWorld Science, Conferences
RSS

PEG-rhSOD advancing in preclinical phase

April 5, 1996

Spartaject busulfan to enter phase I

April 5, 1996

Virend entering phase III

April 5, 1996

BILD-1351 for HSV infection

April 5, 1996

New 5alpha-reductase inhibitor from Merck & Co.

March 26, 1996

Multidrug resistance modulator from Pfizer

March 15, 1996

Xenova to evaluate MDR modulator in phase I

March 15, 1996

Eisai describes antitumor sulfonamide

March 15, 1996

OM-174 shows in vivo antitumor activity

March 15, 1996

IDEC-C2B8 development update

March 15, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 29, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 29, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...